Chia Tai Tianqing Pharmaceutical Group Co., Ltd
https://www.cttq.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Chia Tai Tianqing Pharmaceutical Group Co., Ltd
China’s Cancer Market Is Evolving Fast, Four Multinationals Dominate
In the Chinese pharmaceutical market, sales of anti-tumor drugs have been showing a steady growth trend in recent years as cancer patient numbers continue to rise.
Deal Watch: Japan’s SNBL To Re-Absorb US Spinout Satsuma
Shin Nippon Biomedical Laboratories would take over migraine candidate STS101, now under FDA review. Blue Water Vaccines to pick up BPH drug from Veru.
Deal Watch: GSK Gets Rights To Spero’s Phase III Antibiotic
GSK takes equity stake in Spero, and global rights to tebipenem except for certain Asian markets. Merck KGaA gets rights to Nerviano’s next-generation PARP inhibitor for cancer.
Asia Deal Watch: Astellas, GO Team Up On Targeted Cancer Therapy
Astellas subsidiary Xyphos will partner with GO to discover novel antibodies against two glycoprotein targets. SciNeuro picks up abandoned GSK programs in cardiovascular medicine for potential use in the neurodegeneration space.
Company Information
- Industry
-
Pharmaceuticals
- Generic Drugs
-
Biotechnology
-
Drug Discovery Tools
-
Molecular Diversity
- Natural Products
-
Molecular Diversity
-
Drug Discovery Tools
- Other Names / Subsidiaries
-
- CTTQ PHARMA
- Jiangsu Chia-tai Tianqing Pharmaceutical Co., Ltd. (CTTQ)
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice